The emerging phenotype of long-term survivors with infantile Pompe disease.
| dc.contributor.author | Prater, Sean N | |
| dc.contributor.author | Banugaria, Suhrad G | |
| dc.contributor.author | DeArmey, Stephanie M | |
| dc.contributor.author | Botha, Eleanor G | |
| dc.contributor.author | Stege, Erin M | |
| dc.contributor.author | Case, Laura E | |
| dc.contributor.author | Jones, Harrison N | |
| dc.contributor.author | Phornphutkul, Chanika | |
| dc.contributor.author | Wang, Raymond Y | |
| dc.contributor.author | Young, Sarah P | |
| dc.contributor.author | Kishnani, Priya S | |
| dc.date.accessioned | 2023-05-02T13:35:23Z | |
| dc.date.available | 2023-05-02T13:35:23Z | |
| dc.date.issued | 2012-09 | |
| dc.date.updated | 2023-05-02T13:35:23Z | |
| dc.description.abstract | PurposeEnzyme replacement therapy with alglucosidase alfa for infantile Pompe disease has improved survival creating new management challenges. We describe an emerging phenotype in a retrospective review of long-term survivors.MethodsInclusion criteria included ventilator-free status and age ≤6 months at treatment initiation, and survival to age ≥5 years. Clinical outcome measures included invasive ventilator-free survival and parameters for cardiac, pulmonary, musculoskeletal, gross motor, and ambulatory status; growth; speech, hearing, and swallowing; and gastrointestinal and nutritional status.ResultsEleven of 17 patients met study criteria. All were cross-reactive immunologic material-positive, alive, and invasive ventilator-free at most recent assessment, with a median age of 8.0 years (range: 5.4-12.0 years). All had marked improvements in cardiac parameters. Commonly present were gross motor weakness, motor speech deficits, sensorineural and/or conductive hearing loss, osteopenia, gastroesophageal reflux, and dysphagia with aspiration risk. Seven of 11 patients were independently ambulatory and four required the use of assistive ambulatory devices. All long-term survivors had low or undetectable anti-alglucosidase alfa antibody titers.ConclusionLong-term survivors exhibited sustained improvements in cardiac parameters and gross motor function. Residual muscle weakness, hearing loss, risk for arrhythmias, hypernasal speech, dysphagia with risk for aspiration, and osteopenia were commonly observed findings. | |
| dc.identifier | S1098-3600(21)04537-8 | |
| dc.identifier.issn | 1098-3600 | |
| dc.identifier.issn | 1530-0366 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Elsevier BV | |
| dc.relation.ispartof | Genetics in medicine : official journal of the American College of Medical Genetics | |
| dc.relation.isversionof | 10.1038/gim.2012.44 | |
| dc.subject | Humans | |
| dc.subject | Bone Diseases, Metabolic | |
| dc.subject | Muscle Weakness | |
| dc.subject | Deglutition Disorders | |
| dc.subject | Gastroesophageal Reflux | |
| dc.subject | Hearing Loss | |
| dc.subject | Glycogen Storage Disease Type II | |
| dc.subject | Speech Disorders | |
| dc.subject | alpha-Glucosidases | |
| dc.subject | Autoantibodies | |
| dc.subject | Treatment Outcome | |
| dc.subject | Retrospective Studies | |
| dc.subject | Deglutition | |
| dc.subject | Phenotype | |
| dc.subject | Child | |
| dc.subject | Child, Preschool | |
| dc.subject | Survivors | |
| dc.subject | Female | |
| dc.subject | Male | |
| dc.subject | Enzyme Replacement Therapy | |
| dc.title | The emerging phenotype of long-term survivors with infantile Pompe disease. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Case, Laura E|0000-0002-2941-2186 | |
| duke.contributor.orcid | Jones, Harrison N|0000-0002-4171-980X | |
| duke.contributor.orcid | Young, Sarah P|0000-0002-7671-016X | |
| duke.contributor.orcid | Kishnani, Priya S|0000-0001-8251-909X | |
| pubs.begin-page | 800 | |
| pubs.end-page | 810 | |
| pubs.issue | 9 | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Basic Science Departments | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | Molecular Genetics and Microbiology | |
| pubs.organisational-group | Orthopaedic Surgery | |
| pubs.organisational-group | Pediatrics | |
| pubs.organisational-group | Pediatrics, Medical Genetics | |
| pubs.organisational-group | Duke Clinical Research Institute | |
| pubs.organisational-group | Institutes and Provost's Academic Units | |
| pubs.organisational-group | Initiatives | |
| pubs.organisational-group | Orthopaedic Surgery, Physical Therapy | |
| pubs.organisational-group | Duke Innovation & Entrepreneurship | |
| pubs.organisational-group | Head and Neck Surgery & Communication Sciences | |
| pubs.publication-status | Published | |
| pubs.volume | 14 |
Files
Original bundle
- Name:
- The emerging phenotype of long-term survivors with infantile Pompe disease..pdf
- Size:
- 235.58 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version